FLT3 and acute myeloid leukemia: The primary outcome of an open-label, randomized, phase III trial on quizartinib versus salvage chemotherapy in patients with relapsed or refractory, FLT3/ITD positive AML are expected to be collected by 2018 (NCT02039726).